Skip to Content
Morningstar

Bristol-Myers Squibb Co BMY

Morningstar Rating
Unlock
Stock XNYS Rating as of
$48.30 +0.46 (0.96%)
View Full Chart
As of Delayed Price Pre-Open: $48.35 +0.05
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Price vs Fair Value

View History
BMY is trading at a 23% discount.
Price
$48.30
Fair Value
$69.00
Uncertainty
Medium
1-Star Price
$88.43
5-Star Price
$45.10
Economic Moat
Njk
Capital Allocation
Xvrjvxwr

Bulls Say, Bears Say

Bulls

Bristol is launching several new cancer and immunology drugs that can have high sales trajectories, given the high unmet medical need.

Bears

The acquisition of Celgene brought generic competition for cancer drug Revlimid in 2022, setting up a major growth obstacle over several years, given the planned staggered generic entry.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BMY is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$47.84
Day Range
$47.62–48.41
52-Week Range
$47.58–70.94
Bid/Ask
$48.33 / $48.48
Market Cap
$97.89 Bil
Volume/Avg
1,098 / 15.9 Mil

Key Statistics

Price/Earnings (Normalized)
6.46
Price/Sales
2.23
Dividend Yield (Trailing)
4.84%
Dividend Yield (Forward)
4.97%
Total Yield
10.11%

Company Profile

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Value
Total Number of Employees
34,100
Website
https://www.bms.com

Competitors

Valuation

View More
Metric
BMY
GSK
LLY
Price/Earnings (Normalized)
 6.4610.1889.00
Price/Book Value
 3.314.5965.81
Price/Sales
 2.232.1419.77
Price/Cash Flow
 6.3610.2092.46
Price/Earnings
BMY
GSK
LLY

Financial Strength

Metric
BMY
GSK
LLY
Quick Ratio
 1.240.590.52
Current Ratio
 1.430.880.94
Interest Coverage
 8.249.3014.13
Quick Ratio
BMY
GSK
LLY

Profitability

Metric
BMY
GSK
LLY
Return on Assets (Normalized)
 16.56%10.54%10.22%
Return on Equity (Normalized)
 50.88%50.48%52.03%
Return on Invested Capital (Normalized)
 23.63%21.33%19.27%
Return on Assets
BMY
GSK
LLY
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Drug Manufacturers - General Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
LLY
Eli Lilly and CoQgwzxvgxgTdcrn$709.2 Bil
JNJ
Johnson & JohnsonKgmpbpvyNlhg$351.2 Bil
MRK
Merck & Co IncNglhsztrfQpk$317.2 Bil
ABBV
AbbVie IncZxnfgtkhbBcvw$291.6 Bil
AZN
AstraZeneca PLC ADRSzxczwlhrFcnh$210.7 Bil
RHHBY
Roche Holding AG ADRXvlqfsswnWhsf$194.6 Bil
NVS
Novartis AG ADRHczrtmcRvlbm$189.7 Bil
PFE
Pfizer IncNphzbqvslVwvk$143.8 Bil
AMGN
Amgen IncKxmzvmfbmkRdpj$140.9 Bil
SNY
Sanofi SA ADRVytpsztjLpybm$113.5 Bil

Sponsor Center